Email Updates

Search form

You are here

9 AUGUST 2019 VOLUME 20 ISSUE 30

Media Coverage

  • In Latin America, 40 percent of new HIV infections are in men who have sex with men (MSM) and the recent International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City was the appropriate venue for the first data from the largest ever survey of the region’s MSM to be released.

    August 8, 2019
    General
    aidsmap
  • Researchers are launching a study on HIV self-testing kits with the aim of gaining federal approval for the first such device in Canada. Sean Rourke, a scientist with the Centre for Urban Health Solutions at St. Michael's Hospital, said the clinical trial will begin in Toronto on Wednesday before expanding across the country in coming weeks.

    August 8, 2019
    General
    CBC
  • Since the contraceptive pill transformed women’s lives almost 60 years ago, there’s been precious little innovation in birth control for women. Now a company in San Diego claims to be on the verge of something that could advance the field: a gel women can apply an hour before sex, without having to mess with their hormones.

    August 8, 2019
    General
    Bloomberg Businessweek
  • The Southern United States does not have enough health care providers trained to treat HIV/AIDS, reveals Stateline, a publication of the Pew Charitable Trust. This situation calls into question the realism of the Trump administration’s “Ending the HIV Epidemic: A Plan for America,” which proposes to reduce rates of new HIV infections by 90% nationwide in the next 10 years.

    August 8, 2019
    General
    POZ
  • A leading world scientist is doubtful that cure for HIV/AIDS could be found soon but that other interventions are currently being looked at, and South Africa and other Southern African states are being used for progressive clinical trials of Vaccines.

    August 8, 2019
    Channel Africa
  • Gilead Sciences, Inc. hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates. Such groups have traditionally lobbied for insurance coverage of newer HIV drugs regardless of expense. But at least three US organizations now question whether Gilead’s Descovy would be the best option for most people at risk of exposure.

    August 7, 2019
    Reuters
  • Drugs work stunningly well to control HIV—but not in everyone, and not without side effects. That's why a small cadre of patients known as elite controllers has long fascinated researchers: Their immune system alone naturally suppresses HIV for decades without drugs. Now one team, inspired by success in mice, hopes to endow HIV-infected people with tailormade immune cells that target HIV, in effect creating elite controllers in the clinic.

    August 7, 2019
    Science Magazine
  • An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc’s combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.

    August 7, 2019
    Reuters
  • A South African clinical trial that compared various combinations of anti-HIV drugs has linked two popular antiretrovirals (ARVs) to massive weight gain in women, at an average of 5 kilograms per year. The unexpected weight gain, which was far less pronounced in male participants, has researchers combing through the trial data to better understand why the drugs caused people to put on weight.

    August 7, 2019
    Science Magazine
  • An FDA advisory panel overwhelmingly voted 16-2 to recommend Descovy, the fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF), as pre-exposure prophylaxis (PrEP) to reduce HIV acquisition in men who have sex with men (MSM) and transgender women. But murmurs echoed throughout the room as the FDA's Antimicrobial Drugs Advisory Committee split 8-10 on whether to recommend a PrEP indication for F/TAF in cisgender women.

    August 7, 2019
    MedPage Today
  • A flexible vaginal ring loaded with the HIV antiretroviral dapivirine has been hailed as an exciting new HIV prevention option, particularly for women in sub-Saharan Africa who say the insertable vaginal ring is easier to use and more discreet than existing HIV prevention methods.

    August 6, 2019
    The BodyPro
  • A landmark study evaluating HIV risk and hormonal contraception is under fire, with critics arguing the trial was ethically flawed from the start and that its results may limit already narrow birth-control options for African women.

    August 5, 2019
    The BodyPro
  • In 2014, ViiV Healthcare, a pharmaceutical company dedicated to ending the HIV epidemic, and the Medicines Patent Pool, an organization funded primarily by Unitaid to increase access to medicines in lower-income countries, signed two voluntary licensing agreements.

    August 5, 2019
    Devex
  • When you look at a mountain from a distance, you are excited to reach the peak and see how big and beautiful it looks. When you think of climbing the mountain to the peak you are filled with excitement. You can't wait to get to the top. However, when you start climbing, you can't see the peak anymore. Why? Because you are already at it. You can't tell how far you have gone, so you start guessing. Am I halfway through? Is there a long way to go until I get to enjoy the magnificent view from the top?

    August 4, 2019
    Daily News
  • The government has been asked to make amendment of the HIV/AIDS (Prevention and Control), Act of 2008 on its section 15(2), so that it can allow children at the age of 6-14 years to go for HIV testing without first seeking their guardians and parents' consent.

    August 4, 2019
    General
    All Africa
  • It’s obvious that men’s practices and behaviour are central to women’s vulnerability to HIV. This is why a major focus in the fight against HIV has been on interventions involving work with men and boys to “transform masculinities” specifically on forms of masculinity that reinforce men’s power over women as a way to reduce HIV transmission.

    July 28, 2019
    General
    The Conversation

Published Research

Announcements